FARALLON CAPITAL MANAGEMENT LLC
Position in AVTX — Avalo Therapeutics, Inc.
CIK 909661
SAN FRANCISCO, CA
Position in AVTX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$46,163,040
+$32,487,160 QoQ
Shares Held
2,498,000
+172.7% QoQ
Ownership
4.66%
of shares outstanding
% of Portfolio
0.27%
of 13F equity value
Holder Rank
#8
of 126 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AVTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026FARALLON CAPITAL MANAGEMENT LLC holds $7,178,355,833 across 25 Biotechnology names. AVTX ranks #12 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
13,670,881 | $2,537,793,074 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
10,743,063 | $800,143,332 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
6,348,906 | $778,248,897 | |
| 4 | EXEL |
Exelixis, Inc.
|
13,468,010 | $732,794,424 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
14,309,000 | $506,395,510 | |
| 6 | TNGX |
Tango Therapeutics, Inc.
|
12,277,000 | $383,779,020 | |
| 7 | BEAM |
Beam Therapeutics Inc.
|
10,236,396 | $351,313,110 | |
| 8 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
8,989,098 | $336,372,047 |
All Filings in AVTX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $46,163,040 | 2,498,000 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $13,675,880 | 916,000 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||